{
    "clinical_study": {
        "@rank": "95867", 
        "arm_group": [
            {
                "arm_group_label": "PF-05280014", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Trastuzumab-US", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is to prove that there is no difference in the number of healthy male volunteers\n      that will experience pyrexia (i.e. fever with body temperature of 38\u00b0C or higher) within a\n      24 hour period after administration of a single dose of 6mg/kg of PF-05280014 or trastuzumab\n      sourced from the United States (trastuzumab-US).  The study will also compare the safety of\n      both drugs."
        }, 
        "brief_title": "A Study Evaluating The Safety Of PF-05280014 And Trastuzumab In Healthy Male Volunteers (REFLECTIONS B327-06)", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "Safety evaluation."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Body Mass Index (BMI) of 17.5 to 30.5 kg^m2; and a total body weight >50 kg (110\n             lbs).\n\n          -  Left ventricular ejection fraction (LVEF) within the normal range as measured by\n             echocardiogram (ECHO) within 8 weeks prior to randomization.\n\n          -  Subjects who have previously been exposed to a biologic agent (other than a HER2\n             inhibitor) may enroll provided that at least 3 months have passed since the last\n             administration of that drug.\n\n        Exclusion Criteria:\n\n          -  Evidence or history of clinically significant hematological, renal, endocrine,\n             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or\n             allergic disease (including drug allergies, but excluding untreated, asymptomatic,\n             seasonal allergies at time of dosing).\n\n          -  Previous exposure to an anti-HER2 antibody.\n\n          -  History of serious allergic or anaphylactic reaction to a therapeutic drug or benzyl\n             alcohol."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "162", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02015156", 
            "org_study_id": "B3271006", 
            "secondary_id": "REFLECTIONS B327-06"
        }, 
        "intervention": [
            {
                "arm_group_label": "PF-05280014", 
                "description": "Concentrate for solution for infusion, sterile vial 150 mg, single-dose 6 mg/kg administered as 90-minute infusion on Day 1", 
                "intervention_name": "PF-05280014", 
                "intervention_type": "Biological", 
                "other_name": "Trastuzumab-Pfizer"
            }, 
            {
                "arm_group_label": "Trastuzumab-US", 
                "description": "Concentrate for solution for infusion, sterile vial 440 mg, single-dose 6 mg/kg administered as 90-minute infusion on Day 1", 
                "intervention_name": "Herceptin\u00ae", 
                "intervention_type": "Biological", 
                "other_name": "Trastuzumab-US"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Trastuzumab"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Trastuzumab", 
            "Healthy Male Volunteers", 
            "Single-Dose", 
            "Phase 1", 
            "Biosimilarity"
        ], 
        "lastchanged_date": "April 21, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B3271006&StudyName=A%20Study%20Evaluating%20The%20Safety%20Of%20PF-05280014%20And%20Trastuzumab%20In%20Healthy%20Male%20Volunteers%20%28REFLECTIONS%20B327-06%29"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Overland Park", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "66211"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Overland Park", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "66212"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase 1, Double-Blind, Randomized, Parallel-Group, Single-Dose, 2-Arm, Safety Study Of PF-05280014 And Trastuzumab Sourced From The US Administered To Healthy Male Volunteers", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Incidence of body temperature greater than or equal to 38.0 degrees Celsius", 
            "safety_issue": "Yes", 
            "time_frame": "within 24 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02015156"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Incidence of pyrexia", 
                "safety_issue": "Yes", 
                "time_frame": "within 24 hours"
            }, 
            {
                "measure": "Severity of pyrexia", 
                "safety_issue": "Yes", 
                "time_frame": "within 24 hours"
            }, 
            {
                "measure": "Timing of pyrexia", 
                "safety_issue": "Yes", 
                "time_frame": "within 24 hours"
            }, 
            {
                "measure": "Seriousness of pyrexia", 
                "safety_issue": "Yes", 
                "time_frame": "within 24 hours"
            }, 
            {
                "measure": "Relationship of study therapy to pyrexia", 
                "safety_issue": "Yes", 
                "time_frame": "within 24 hours"
            }, 
            {
                "measure": "Incidence of body temperature greater than or equal to 38.0\u00b0C and/or use of concomitant treatment associated with fever suppression", 
                "safety_issue": "Yes", 
                "time_frame": "within 24 hours"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}